Objectives: To evaluate the overall and individual quality of mean uterine artery pulsatility index (UtPI) measurements performed in a Danish multi-centre validation study of first trimester screening for pre-eclampsia. Methods: Women attending first trimester screening for aneuploidies in six hospitals from May 2019 to February 2020 were offered to participate in the pre-eclampsia screening validation study. As part of the project, mean UtPI was measured on all participants by FMF certified sonographers. We performed quality assessment of UtPI measurements, including graphical visualisation of UtPI data corrected for maternal weight and gestational age using scatter plots. Inter-operator comparisons were illustrated via forest plots (mean and standard deviation) and monthly trends were plotted in cumulative sum (CUSUM) charts. In order to provide individual feedback, plots were also made for each UtPI operator. Results: We retrieved data on 3,969 UtPI measurements from 82 sonographers. Overall, there was evidence of a negative bias relative to the current FMF reference distribution. UtPI measurements were lower than expected (bias = 0.06 SD Log10[MoM]). Most sonographers (84 % [69/82]) measured UtPI within the acceptable range (bias < 0.3 SD Log10[MoM]). Conclusions: UtPI measurements were overall slightly lower than expected according to the FMF reference. Each sonographer will receive individual feedback, and a reevaluation of the performance is scheduled in three months. VP50.02 Ophthalmic artery Doppler as an auxiliary method in the differentiation between pre-eclampsia and chronic hypertension in pregnant women
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.